18 F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy by Nicastro, Nicolas et al.
Vol.:(0123456789) 
Journal of Neurology (2020) 267:341–349 
https://doi.org/10.1007/s00415-019-09566-9
ORIGINAL COMMUNICATION
18F‑AV1451 PET imaging and multimodal MRI changes in progressive 
supranuclear palsy
Nicolas Nicastro1,2  · Patricia Vazquez Rodriguez3 · Maura Malpetti3 · William Richard Bevan‑Jones3 · 
P. Simon Jones3 · Luca Passamonti3,4 · Franklin I. Aigbirhio5 · John T. O’Brien1 · James B. Rowe3,6
Received: 6 September 2019 / Revised: 27 September 2019 / Accepted: 30 September 2019 / Published online: 22 October 2019 
© The Author(s) 2019
Abstract
Objectives Progressive supranuclear palsy (PSP) is characterized by deposition of straight filament tau aggregates in the grey 
matter (GM) of deep nuclei and cerebellum. We examined the relationship between tau pathology (assessed via 18F-AV1451 
PET) and multimodal MRI imaging using GM volume, cortical thickness (CTh), and diffusion tensor imaging (DTI).
Methods Twenty-three people with clinically probable PSP-Richardson’s syndrome (age 68.8 ± 5.8 years, 39% female) and 
23 controls underwent structural 3 T brain MRI including DTI. Twenty-one patients also had 18F-AV1451 PET imaging. 
Voxelwise volume-based morphometry, surface-based morphometry, and DTI correlations were performed with 18F-AV1451 
binding in typical PSP regions of interest (putamen, thalamus and dentate cerebellum). Clinical impairment was also assessed 
in relation to the different imaging modalities.
Results PSP subjects showed GM volume loss in frontotemporal regions, basal ganglia, midbrain, and cerebellum (FDR-
corrected p < 0.05), reduced CTh in the left entorhinal and fusiform gyrus (p < 0.001) as well as DTI changes in the corpus 
callosum, internal capsule, and superior longitudinal fasciculus (FWE-corrected p < 0.05). In PSP, higher 18F-AV1451 bind-
ing correlated with GM volume loss in frontal regions, DTI changes in motor tracts, and cortical thinning in parietooccipital 
areas. Cognitive impairment was related to decreased GM volume in frontotemporal regions, thalamus and pallidum, as well 
as DTI alteration in corpus callosum and cingulum.
Conclusion This cross-sectional study demonstrates an association between in vivo proxy measures of tau pathology and 
grey and white matter degeneration in PSP. This adds to the present literature about the complex interplay between structural 
changes and protein deposition.
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Introduction
Progressive supranuclear palsy (PSP) encompasses a broad 
spectrum of motor, cognitive, and behavioural impairments. 
These include akinesia, postural instability with early falls, 
oculomotor deficits, fronto-executive dysfunction, and neu-
ropsychiatric features such as apathy and impulsivity [1, 2]. 
Neuropathological studies have shown that PSP is character-
ized by intra-neuronal and astrocytic aggregation of toxic 
microtubule-associated protein tau (of four-repeat tau iso-
forms, with straight filaments) [3, 4]. Using 18F-AV1451 
positron emission tomography (PET) allows to quantify and 
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localise in vivo tau burden. 18F-AV1451 binding is consist-
ently increased in the basal ganglia, thalamus, and dentate 
cerebellum in patients with PSP relative to controls [5–7], 
mirroring its neuropathological distribution [4]. Albeit 18F-
AV1451 affinity for tau inclusions in non-AD tauopathies 
is less than in AD [8–10] and is not specific to tau [11], the 
distribution of 18F-AV1451 shows distinctive features in PSP 
[6]. Therefore, where high clinic-pathological correlations 
indicate likely PSP tau pathology, 18F-AV1451 can be used 
to quantify it and compare to other disease processes such 
as white matter pathology.
Multimodal structural imaging in PSP usually shows grey 
matter (GM) volume loss in midbrain, striatum and frontal 
cortex, cortical thickness (CTh) reduction in frontal areas, 
and white matter damage in cerebellar peduncles, thalamic 
radiations and corpus callosum [12–18].
Despite the separate insights from 18F-AV1451 PET and 
structural imaging, the relationship between tau burden 
and grey/white matter degeneration in PSP has remained 
unknown. The aim of the study was, therefore, to assess GM 
volume, CTh, and diffusion tensor imaging (DTI) changes in 
PSP compared to Controls; second, to perform correlation 
analyses of structural MRI/DTI changes with 18F-AV1451 
in high-binding regions previously shown to be involved in 
PSP [6]. In addition, we assessed motor and cognitive clini-
cal correlations of both 18F-AV1451 binding and structural 
MRI/DTI imaging. Considering the atrophy and extensive 
white matter damage observed in PSP in the previous stud-
ies, we predicted a GM volume loss and microstructural dis-
ruption related to higher 18F-AV1451 binding and that the 
severity of these changes is related to clinical impairment.
Methods
Participants
The present study is part of the Neuroimaging of Inflamma-
tion in MemoRy and Other Disorders (NIMROD) protocol 
[19]. We included 23 participants with probable PSP (PSP-
Richardson syndrome) who were recruited according to 
NINDS-SPSP 1996 criteria [3] but reconfirmed as meeting 
the current clinical diagnostic criteria of probable PSP-RS 
[2]. 23 similarly aged healthy controls were also recruited, 
with MMSE > 26/30, absence of regular memory com-
plaints, and no history of major neurological, psychiatric, 
or significant medical illness. Patients were identified from 
the regional specialist PSP-clinic at the Cambridge Univer-
sity Hospitals NHS Trust. Healthy controls were recruited 
via the Dementias and Neurodegenerative Diseases Research 
Network volunteer register. Informed written consent was 
obtained in accordance with the Declaration of Helsinki. The 
study received a favourable opinion from the East of England 
Ethics Committee (Cambridge Central Research, Ref. 13/
EE/0104). Clinical and cognitive assessment included mini-
mental state examination (MMSE), revised Addenbrooke’s 
Cognitive Examination (ACER), and the PSP rating scale 
(PSP-RS) for PSP subjects [20].
MRI acquisition and preprocessing
Participants underwent MRI imaging acquired on a 3 T 
scanner (Siemens Magnetom Tim Trio) using a magnetiza-
tion-prepared rapid gradient echo (MPRAGE) T1-weighted 
sequence (repetition time = 2300 ms, echo time = 2.98 ms, 
field of view = 240 × 256  mm2, 176 slices, flip angle = 9°, 
isotropic 1 mm voxels).
GM volume and CTh were assessed using Computational 
Anatomy Toolbox 12 (CAT12, Structural Brain Imaging 
Group, University of Jena, Germany) running in Mat-
lab R2018b version 9.5 (MathWorks Inc., Sherborn, MA, 
USA). CAT12 allows volume-based morphometry (VBM) 
evaluation by providing the voxelwise estimation of the local 
amount or volume of a specific tissue compartment [21]. 
The automated pipeline incorporates different preprocess-
ing steps, including spatial registration to a reference brain, 
tissue segmentation into GM, white matter and CSF, and 
bias correction of intensity non-uniformities. Smoothing was 
performed using a full-width at half maximum (FWHM) 
of 8 mm as recommended. CAT12 can additionally assess 
CTh and central surface of the left and right hemispheres 
based on the projection-based thickness method [22]. Using 
a tissue segmentation to estimate the white matter distance, 
it then projects the local maxima (which is equal to the 
CTh) to other GM voxels by using a neighbour relationship 
described by the white matter distance. Projection-based 
thickness allows the handling of partial volume informa-
tion, sulcal blurring, and sulcal asymmetries without explicit 
sulcus reconstruction [22]. Topological correction, spherical 
mapping, and spherical registration are performed to obtain 
vertexwise CTh. Finally, surface maps are smoothed using a 
15 mm-FWMH for group comparisons and clinical/imaging 
correlations.
Diffusion-weighted images were acquired with 
a 65-direction encoding scheme, 2  mm thickness, 
TE = 106 ms, TR = 11,700 ms, field of view = 192 × 192 
 mm2. 64 volumes were acquired with a b value of 1000 s/
mm2 following an initial volume with a b value of 0 s/
mm2. The data were preprocessed with the FSL 6.0 soft-
ware package (https ://www.fmrib .ox.ac.uk/fsl) using FSL 
Diffusion Toolbox. First, the series was adjusted for head 
movement and eddy currents using eddy and realigned to 
the b0 image. A brain mask was then produced by applying 
the Brain Extraction Tool (BET) to the (mean) b0 image. 
DTIfit was next used to independently fit the diffusion ten-
sor at each voxel, resulting in the derivation of fractional 
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anisotropy (FA), mean (MD) and radial diffusivity (RD) 
maps. Tract-based spatial statistics (TBSS) was then used 
to align each subject’s FA image to a pre-identified tar-
get FA image (FMRIB_58) [23], followed by affine reg-
istration into the Montreal Neurological Institute (MNI) 
MNI152 space. A mean FA image and skeleton were cre-
ated from all subjects and each individual’s FA image was 
then projected onto the skeleton, with a threshold of 0.2 
applied to the mean skeleton to include white matter tracts 
that were common across all subjects and to exclude vox-
els that may contain GM or CSF. The aligned DTI param-
eter map of each subject was then back-projected onto the 
mean skeleton. In addition, other DTI parameters (i.e., MD 
and RD) were aligned by applying the original FA non-
linear spatial transformations to the corresponding datasets 
and projecting them onto the mean FA skeleton.
18F‑AV1451 PET acquisition and preprocessing
21 PSP participants underwent 18F-AV-1451 PET imaging. 
The radioligand was prepared at the Wolfson Brain Imag-
ing Centre, University of Cambridge, UK. PET scanning 
was performed on a GE Advance or a GE Discovery 690 
PET/CT (General Electric Healthcare, Chicago, Illinois, 
USA). A 15-min 68Ge/68 Ga transmission scan was used 
for attenuation correction. The emission protocol was as 
follows: 90 min dynamic imaging following a 370 MBq 
18F-AV1451 injection. Each emission image series was 
aligned using SPM8 to correct for patient motion during 
data acquisition (www.fil.ion.ucl.ac.uk/spm/softw are/
spm8). The mean aligned PET images were rigidly reg-
istered to the T1-weighted image to extract values from 
both the Hammers atlas regions of interest (ROIs) and 
those in a reference tissue defined in the superior cerebel-
lar GM using a 90% GM threshold on the GM probabil-
ity map produced by SPM8 smoothed to PET resolution 
[24]. Regional PET data were corrected for CSF partial 
volumes. 18F-AV1451 non-displaceable binding poten-
tial  (BPND) was determined for each ROI using a basis 
function implementation of the simplified reference tissue 
model [25]. As shown in a previous publication [6], our 
PSP cohort had significantly higher 18F-AV1451  BPND in 
the putamen, pallidum, thalamus, midbrain, and cerebellar 
dentate gyrus (all p < 0.02). Considering the high collin-
earity between some of these respective  BPND values, we 
included for the present study the individual 18F-AV1451 
binding of thalamus, putamen and cerebellar dentate gyrus 
for correlational analyses with multimodal MRI imaging. 
However, as tau deposition is prominent in other PSP-
specific regions, we performed the same correlational 
analyses using 18F-AV1451 binding in the midbrain, fron-
tal lobe, and the average of all cortical ROIs.
Statistical analyses
Demographic data were analyzed with Stata software Ver-
sion 14.2 (College Station, TX). Assessment of distribution 
for continuous variables was performed with Shapiro–Wilk 
test and visualization of histogram plots, followed by t test or 
Mann–Whitney U, accordingly. Categorical variables were 
compared with Chi-Square test. Statistical significance was 
considered when p < 0.05.
GM volume and CTh comparisons between PSP subjects 
and controls were performed in CAT12 with a 2-sample t test 
using age and gender as covariates. For VBM, total intrac-
ranial volume (TIV) was also added as a covariate. Cor-
relation of voxelwise GM volume/CTh maps with regional 
18F-AV1451  BPND was performed using multiple regressions 
with individual 18F-AV1451 binding in the thalamus, puta-
men, and dentate gyrus as the variable of interest, and age, 
gender, PSP-RS, and TIV (only for VBM) as covariates. 
A significant statistical threshold of p < 0.05 false discov-
ery rate (FDR)-corrected was considered. As the present 
study involves relatively modest groups of subjects, we also 
showed uncorrected p < 0.001 results using an extent thresh-
old (k) of the expected voxels/vertices per cluster.
Regarding DTI, the randomise function in FSL was 
implemented to identify group differences in DTI metrics 
between PSP and controls, using an independent sample t 
test, with age and gender as covariates. Similarly, voxel-
wise correlational models between DTI measures and aver-
age 18F-AV1451 binding in specific ROIs for PSP subjects 
included age, gender, PSP-RS as covariates. Statistical sig-
nificance was determined using non-parametric permutation 
testing (n = 10′000 permutations), applying threshold-free 
cluster enhancement (TFCE) and adjusting for multiple 
comparisons with familywise error (FWE) p < 0.05. Ana-
tomical labelling of significant TBSS white matter clusters 
was facilitated using the John Hopkins—ICBM white matter 
atlas, available as part of the FSL package.
For PSP subjects, correlation analyses between clinical 
scales (ACER and PSP-RS) and regional 18F-AV1451  BPND 
or GM/CTh/DTI maps were performed using multiple lin-
ear regressions using the same covariates as above (age and 
gender + TIV for VBM). We also performed Spearman cor-
relation between clinical scores and regional 18F-AV1451 
binding.
Results
Demographics
Demographic and clinical characteristics of PSP and con-
trols are shown in Table 1. Both groups were compara-
ble in terms of age, gender, and education attainment. As 
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expected, cognitive scores (i.e., MMSE and ACER) were 
lower in the PSP group (p = 0.01 and p < 0.001, respec-
tively). Average disease duration at scan for the PSP group 
was 4.6 ± 2.1 years (range 1.5–9).
GM/CTh/DTI group comparisons
Comparisons between groups revealed GM volume loss for 
PSP subjects in both cortical and subcortical regions, includ-
ing right medial frontal, right temporal pole, left supplemen-
tary motor area (SMA), as well as bilateral caudate nucleus, 
putamen, thalamus, midbrain, and cerebellum (FDR-cor-
rected p < 0.05). In addition, we observed reduced CTh for 
PSP subjects in the left entorhinal and fusiform gyri (uncor-
rected p < 0.001, k = 41 vertices). DTI analyses confirmed 
that relative to controls, PSP subjects had diffuse white 
matter damage in the corpus callosum (genu, body, and 
splenium), bilateral internal capsule, corona radiata, pos-
terior thalamic radiations, cingulate white matter, superior 
longitudinal fasciculus (SLF), sagittal stratum, and uncinate 
fasciculus (FWE-corrected p < 0.05). These abnormalities 
were consistent across the three DTI metrics (i.e., decreased 
FA, increased MD and RD for PSP) (Fig. 1).
Voxelwise correlation of structural MRI/DTI imaging 
and 18F‑AV1451 binding
Higher thalamic, putaminal, and cerebellar dentate 18F-
AV1451  BPND were correlated with lower GM volume 
(all uncorrected p < 0.001, k = 20 voxels) (Fig. 2), more 
pronounced cortical thinning (all uncorrected p < 0.001, 
k = 36 vertices) (Fig. 3) and altered white matter metrics 
Table 1  Clinical characteristics 
of included subjects
Values are mean ± standard deviation (range)
*Student t test
§ Chi-square test
# Mann–Whitney U test
NA not applicable
PSP (n = 23) Controls (n = 23) P value
Age, years 68.8 ± 5.8 (52–79) 68.7 ± 7.3 (55–81) 0.95*
Female participants 39% (9/23) 48% (11/23) 0.55§
Education, years 12.2 ± 2.1 (10–17) 13.5 ± 2.5 (9–17) 0.06*
MMSE 26.0 ± 4.5 (13–30) 28.7 ± 1.1 (26–30) 0.01#
ACER 78.2 ± 16.5 (36–95) 91.3 ± 6.3 (75–99) < 0.001#
PSP-RS 48.0 ± 16.3 (25–77) – NA
Disease duration at scan, years 4.6 ± 2.1 (1.5–9) – NA
Fig. 1  Multimodal MRI/DTI 
group comparisons between 
PSP and controls showing GM 
volume loss (red), DTI changes 
(increased RD, blue), and 
cortical thinning (yellow–red) 
for PSP subjects. Color bars 
represent T-scores
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Fig. 2  GM volume loss 
(grey) in relation to thalamic, 
putaminal and dentate 18F-
AV1451  BPND in PSP subjects 
(p < 0.001, k = 20 voxels). Color 
bars are T-scores
Fig. 3  CTh reduction (yel-
low–red) related to thalamic, 
putaminal and dentate 18F-
AV1451  BPND in PSP subjects 
(p < 0.001, k = 36 vertices). 
Color bars are T-scores
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(e.g., increased MD/RD or decreased FA) (FWE-corrected 
p < 0.05) (Fig. 4). More specifically, higher thalamic 18F-
AV1451  BPND was associated with GM volume reduction 
in bilateral SMA, precentral gyrus, and right cerebellum; 
decreased CTh in right latero-occipital, fusiform, and infe-
rior parietal gyri; and DTI alterations in bilateral internal 
capsule, corona radiata, posterior thalamic radiations, SLF, 
body of corpus callosum, cingulate white matter, and supe-
rior fronto-occipital fasciculus.
Higher putaminal 18F-AV1451  BPND was correlated with 
lower GM volume in bilateral precentral gyrus, left SMA 
and parahippocampal gyrus, as well as right superior and 
middle frontal gyri; reduced CTh in the right precuneus and 
DTI alterations in bilateral internal capsule, corona radiata, 
cingulate white matter, and SLF.
Finally, higher 18F-AV1451  BPND in the cerebellar den-
tate gyrus was correlated with GM volume loss in bilateral 
cerebellum and precentral gyrus, right superior and middle 
frontal gyri, and left thalamus; CTh reduction in left supe-
rior and middle frontal gyri; and DTI alterations in genu and 
body of corpus callosum, bilateral corona radiata, SLF and 
superior fronto-occipital fasciculus, right internal capsule, 
posterior thalamic radiations, and cingulate white matter.
Correlational analyses were additionally performed using 
18F-AV1451 binding in the midbrain, frontal lobe, and global 
cortical level to assess whether these PSP-prone regions in 
terms of tau pathology had specific structural impairment 
related to their 18F-AV1451 binding. Higher midbrain 
18F-AV1451 was related to right temporal GM reduction, 
whereas frontal and global binding was negatively correlated 
with bilateral superior frontal and precentral GM reduction 
(p < 0.001, k = 20 voxels). No significant correlation was 
observed between these three ROI’s 18F-AV1451 and corti-
cal thinning (p > 0.001), whereas their 18F-AV1451 binding 
was associated with altered DTI (increased RD) in body of 
corpus callosum and motor tracts (FWE p < 0.05).
Clinical correlations with 18F‑AV1451 and MRI 
imaging
Higher PSP-RS score correlated with GM volume loss in 
bilateral middle cingulate gyrus, right middle temporal 
gyrus, left fusiform and middle occipital gyri, bilateral 
cuneus, and left cerebellum (p < 0.001, k = 21 voxels). A 
higher PSP-RS score was also associated with increased RD 
in white matter facing bilateral middle temporal gyrus, right 
lateral occipital gyrus and cuneus (p < 0.001, k = 25 vox-
els). There was no significant correlation with CTh and 18F-
AV1451  BPND. Using Spearman correlation of 18F-AV1451 
and PSP-RS, we observed a trend between higher PSP-RS 
and higher midbrain 18F-AV1451 binding (rho = 0.34, 
p = 0.13).
Lower ACER score was correlated with lower GM 
volume in bilateral medial temporal regions (hippocam-
pus, amygdala, and entorhinal cortex), bilateral temporal 
poles, right superior frontal gyrus, thalamus, and pallidum 
(p < 0.001, k = 20 voxels). A lower ACER was also related 
to CTh reduction in left superior and middle temporal 
gyrus (p < 0.001, k = 37 vertices), as well as white matter 
deficits (increased RD) in the genu and body of corpus cal-
losum, bilateral internal capsule and corona radiata, right 
cingulate white matter and SLF (FWE-corrected p < 0.05). 
We found a trend between higher ACER score and lower 
Fig. 4  DTI changes (increased 
RD, blue) correlated with tha-
lamic, putaminal, and dentate 
18F-AV1451  BPND in PSP sub-
jects (FWE-corrected p < 0.05)
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18F-AV1451 binding in dentate gyrus using Spearman cor-
relation (rho = − 0.32, p = 0.16).
Discussion
Using multimodal MRI imaging with VBM, SBM and DTI, 
we demonstrate that higher 18F-AV1451 binding in tau-prone 
regions affected by PSP was correlated with changes in grey 
and white matter. We interpret these findings in terms of a 
correlation between tau pathology and structural integrity 
while recognizing important caveats below.
In comparing PSP patients with controls independently 
of 18F-AV1451 binding, extensive structural impairment was 
observed, with GM volume loss affecting frontotemporal 
regions, basal ganglia, midbrain and cerebellum, CTh reduc-
tion in left entorhinal and fusiform gyri, and DTI changes 
in the corpus callosum, internal capsule, corona radiata, and 
posterior thalamic radiations, among others. These results 
are in keeping with the previous observations [12–14, 17, 
18], suggesting a key role of grey and white matter changes 
in the pathophysiology of PSP, especially the PSP-Richard-
son syndrome [26].
We also observed that 18F-AV1451 in high-binding 
regions for PSP (i.e., thalamus, putamen, and cerebellar 
dentate gyrus) was correlated with GM volume loss mainly 
in anterior regions, i.e., SMA, superior and middle fron-
tal and precentral gyri, while increased PET binding was 
related to cortical thinning in posterior regions (e.g., lateral-
occipital, fusiform gyrus and precuneus). In addition, 18F-
AV1451  BPND was associated with altered DTI in motor 
tracts (corona radiata, internal capsule), posterior thalamic 
radiations and SLF, the latter being particularly involved 
in spatial attention, oculomotor function, and motor behav-
iour [27]. Higher 18F-AV1451 binding in the thalamus and 
dentate gyrus was also related to white matter disruption 
in the body of corpus callosum, whose fibres pass through 
the corona radiata to reach the brain surface, the cingulum 
(which is densely connected to the thalamus and spinotha-
lamic tract) and superior fronto-occipital fasciculus. These 
cross-modal association shed light onto the intricate in vivo 
relationship between the integrity of connecting fibres and 
18F-AV1451 binding. Due to the cross-sectional design of 
our study, it is still unclear whether microstructural damage 
is a direct consequence of tau pathology in the white mat-
ter (as observed post mortem) or consecutive to Wallerian 
degeneration [28]. However, considering the GM volume 
loss and DTI signal impairment taking place in similar 
anterior regions in relation to higher 18F-AV1451 binding, 
our results suggest that white matter degeneration is at least 
partly secondary to GM volume loss. Using a sparse canoni-
cal correlation analysis between DTI and 18F-AV1451 PET 
imaging, Sintini et al. recently demonstrated that higher 
18F-AV1451 binding in cerebellar dentate, red nucleus and 
subthalamic nucleus was associated with altered DTI in sag-
ittal stratum, corona radiata and superior cerebellar peduncle 
[29].
At variance with GM volume and DTI changes observed 
in anterior brain regions, increased 18F-AV1451 binding was 
associated with cortical thinning in more posterior (parieto-
occipital) areas. These findings are of particular interest as 
CTh reduction in PSP is usually described in frontal regions, 
with little changes observed in longitudinal studies [16]. 
Therefore, with the present correlational analyses, we were 
able to tackle more subtle posterior cortical changes in rela-
tionship to a PET proxy assessing tau deposition.
In addition to these three regions (i.e., putamen, thala-
mus, and dentate gyrus), we performed correlational analy-
ses of MRI changes with midbrain, frontal lobe, and global 
cortical 18F-AV1451 binding, as they are PSP-prone regions 
for tau deposition. Although unspecific white matter changes 
involving corpus callosum and motor tracts were related to 
higher 18F-AV1451 uptake in these ROIs, there was no sig-
nificant cortical thinning in relationship to it. In addition, 
higher frontal and global 18F-AV1451 was negatively cor-
related with frontal GM volume loss. This highlights the fact 
that the three high-binding 18F-AV1451 regions we initially 
selected (i.e. thalamus, putamen, and dentate gyrus) have 
specific relationships with structural GM loss, as remote 
effects on GM involving both cortical thinning and volume 
loss are specifically related to higher 18F-AV1451 binding 
in diencephalic and cerebellar regions. One must insist that 
these are spatiotemporal relationships using a cross-sectional 
approach and that it does not necessarily involves causality. 
However, considering our modest cohort and a relatively 
stringent significance threshold, we believe that this brings 
novel insights into the complex relationship of a tau PET 
proxy with structural changes.
With regard to multimodal imaging correlates of clini-
cal motor (PSP-RS) or cognitive (ACER) impairment, 
our results pointed out to a lack of correlation with 18F-
AV1451 binding. This is in accordance with Schonhaut 
et al. [7] but contrasts with Smith et al. [9], who found a 
correlation between pallidal 18F-AV1451 binding and PSP-
RS using Spearman correlations. One explanation could be 
the relatively small sample sizes or early disease stage of 
our patients. In addition, we assessed correlation using lin-
ear regressions adjusting for age and gender. In fact, when 
performing a Spearman correlation instead, we observed a 
trend between higher midbrain AV1451 and higher PSPRS 
score (rho = 0.34, p = 0.13). In addition, lower 18F-AV1451 
binding in the dentate gyrus was associated at the trend 
level with higher ACER (rho = − 0.32, p = 0.16). In AD, 
18F-AV1451 binding in the temporal cortex was negatively 
related to temporal (especially its medial portion) CTh 
change [30]. In addition, Bejanin et al. [31] showed that 
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tau deposition was related in a region-specific manner to 
cognitive decline. That 18F-AV1451 is a more sensitive 
marker of paired helical filaments than straight filamentous 
might also play a role.
Conversely, we did find that lower cognitive performance 
according to ACER score was significantly associated with 
reduced GM volume in mediotemporal regions, right supe-
rior frontal gyrus, thalamus, and pallidum. In addition, lower 
ACER correlated with impaired diffusion metrics in the 
corpus callosum, cingulum, motor tracts, and SLF. These 
highlight the prominent role of frontal dysfunction in PSP 
[32, 33], as these white matter tracts are densely connected 
to the frontal lobe [34]. In a previous study, Piattella et al. 
showed that MMSE score in PSP was correlated with whole 
white matter mean FA [18].
While PSP-RS score was not associated with specific cor-
tical thinning, we observed altered GM and DTI in bilateral 
temporal and right occipital regions, highlighting the close 
relationship between atrophy and white matter degeneration 
according to motor impairment.
Our study is not without limitations. First, our results 
would require confirmation in larger and independent sam-
ples. Second, the present relationship between 18F-AV1451 
and structural imaging is based on a cross-sectional design: 
longitudinal studies are, therefore, required to fully assess 
the spatial and temporal interplay between grey/white mat-
ter integrity and 18F-AV1451 in PSP, and test causal mod-
els of pathology in humans. Moreover, due to the relatively 
modest sample size, most of our correlational results were 
uncorrected for multiple comparisons. We, however, used a 
stringent significance threshold (p < 0.001) and extent clus-
ter threshold. In addition, 18F-AV1451 off-target binding 
is a caveat to our interpretation. Neuromelanin-containing 
cells in the substantia nigra and monoamine oxidase in the 
striatum are bound by this ligand [35, 36]. However, we 
recently showed that off-target binding in basal ganglia, cor-
tex or adjacent white matter is not sufficient an explanation, 
as postmortem data did not show relevant neuromelanin-
containing cells [6]. The very high clinic–pathological cor-
relations in PSP–Richardson syndrome preclude TDP43 [11] 
or concurrent AD pathology as an alternative explanation, 
noting that the six patients in our study who have come to 
post-mortem examination were confirmed as PSP without 
significant dual pathology.
In conclusion, we present evidence of the in vivo associa-
tion between structural brain integrity and 18F-AV1451 in 
PSP. Longitudinal studies would be helpful to determine the 
dynamic changes occurring for both tau deposition and grey/
white matter changes. Tau PET probes more specific and 
sensitive for straight filaments would also enable confirma-
tion of the complex interplay between cortical tau aggrega-
tion, grey/white matter degeneration and disease progression 
in PSP.
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